Tvardi Therapeutics Inc. has approved a one-time retention compensation package for its named executive officers. Chief Executive Officer Dr. Imran Alibhai received an option to purchase 47,500 shares, while Chief Medical Officer Dr. John Kauh and Chief Financial Officer Dan Conn each received options for 17,500 shares. The options have an exercise price based on the closing per-share price on the grant date, with 25% of the shares vesting on the one-year anniversary of December 16, 2026, and the remainder vesting in equal monthly installments over the next three years. Additionally, the company adopted a Severance and Change in Control Plan providing severance and equity vesting acceleration benefits to eligible employees, including the named executive officers, in the event of certain qualifying terminations.